NPS Pharmaceuticals price target raised to $45 from $30 at Janney Capital Janney continues to recommend NPS Pharmaceuticals following recent share strength. The analyst has learned that some patient have been able to get reimbursement for Gattex without taking IV total parenteral nutrition, which implies insurers have expanded the label. Shares are Buy rated.
News For NPSP From The Last 14 Days
Check below for free stories on NPSP the last two weeks.
NPS Pharmaceuticals weakness attributed to comments on Natpara NPS Pharmaceuticals management said at a conference hosted by Deutshce Bank that it does not know if an FDA panel will be need for Natpara, according to Bloomberg. The company said it doesn't expect a priority review for Natpara, the news service added. Shares of NPS have fallen to session lows, down 7.7% to $24.04.
Deutsche Bank to host a conference BioFest is being held in Boston on December 2-3 with webcasted company presentations to begin on December 3 at 7:50 am; not all company presentations may be webcasted. Webcast Link